[{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"EA Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"\u201cMOVICOL\u00ae HD\u201d Launched - A New Dosage Form Added to Polyethylene Glycol Chronic Constipation Treatment for the First Time in Japan","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Mochida Pharmaceutical","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Idorsia Japan Announces Positive Results With Daridorexant In A Phase 3 Study Of Japanese Patients With Insomnia","therapeuticArea":"Sleep","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Sleep","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Mochida Pharmaceutical
The study met both primary and secondary efficacy endpoint measures ACT-541468 (Daridorexant) significantly improved sTST from baseline compared to placebo at 28 days (p<0.001 for 50 mg, p=0.042 for 25 mg).
MOVICOL® HD is a high dose formulation of existing “MOVICOL® LD”, the first polyethylene glycol indicated for treatment of chronic constipation1) in Japan. MOVICOL® HD contains the same active ingredients in double the quantity of MOVICOL® LD per sachet.